Vir Biotechnology, Inc.

corporate_fare Company Profile

Vir Biotechnology, Inc.

VIR·NASDAQ·Life Sciences·CIK 0001706431

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines for serious infectious diseases and cancer by enhancing the immune system. The company focuses on developing therapies that improve the immune system's ability to overcome evasion tactics used by cancer cells and viruses. Vir Bio's clinical development pipeline includes investigational therapies for hepatitis delta virus (HDV) and multiple solid tumors. For hepatitis delta, the company has initiated its registrational ECLIPSE clinical program, which evaluates the combination of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD). This program consists of three ongoing randomized, controlled trials: ECLIPSE 1, ECLIPSE 2, and ECLIPSE 3. ECLIPSE 1 and ECLIPSE 3 have completed enrollment. Topline results for ECLIPSE 1 are anticipated in the fourth quarter of 2026, while topline results for ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027.

Vir Biotechnology, Inc. (NASDAQ:VIR) is a publicly traded company in the Life Sciences sector. Wiseek monitors VIR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair (2026-06-10)
Vir Biotechnology to Present Complete Phase 2 Solstice Data for Hepatitis Delta (2026-05-18)
Vir Biotechnology Finalizes Astellas Collaboration for Prostate Cancer Drug VIR-5500, Securing $315M Upfront & Equity (2026-05-06)
Vir Biotechnology Secures $172.5M in Public Offering, Extends Cash Runway to H2 2028, and Advances Key Pipeline Programs (2026-05-06)
Vir Biotechnology Announces Departure of Chief Medical Officer (2026-04-10)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

$68.56M

Net Income

-$437.99M

Diluted EPS

-$3.16

Op. Cash Flow

-$391.78M

Free Cash Flow

-$396.61M

Gross Profit

$68.53M

Operating Income

-$479.33M

Cash & Equivalents

$232.19M

Debt / Equity

0.00×

Net Margin

-6.39×

Shares Outstanding

139.47M sh

Source: 10-K · filed 2026-02-23 · accession 0001628280-26-010749

Browse all tickers starting with V →

show_chartPrice Chart

Loading chart...

feed VIR - Latest Insights

Filing Type

Date Range

VIR

Jun 10, 2026, 4:27 PM EDT

Filing Type: 8-K

Importance Score:

Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair

Price at Filing: $7.80

Real-time Price: $8.46

Change: +$0.660 (+8%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

VIR

May 18, 2026, 4:07 PM EDT

Source: Reuters

Importance Score:

Vir Biotechnology to Present Complete Phase 2 Solstice Data for Hepatitis Delta

Price at Filing: $8.77

Real-time Price: $8.46

Change: -$0.310 (-4%)

Market Cap: $1.452B

Sentiment: Neutral

View Wiseek Article

VIR

May 06, 2026, 5:32 PM EDT

Filing Type: 10-Q

Importance Score:

Vir Biotechnology Finalizes Astellas Collaboration for Prostate Cancer Drug VIR-5500, Securing $315M Upfront & Equity

Price at Filing: $10.45

Real-time Price: $8.46

Change: -$1.99 (-19%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

VIR

May 06, 2026, 4:11 PM EDT

Filing Type: 8-K

Importance Score:

Vir Biotechnology Secures $172.5M in Public Offering, Extends Cash Runway to H2 2028, and Advances Key Pipeline Programs

Price at Filing: $10.15

Real-time Price: $8.46

Change: -$1.69 (-17%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

VIR

Apr 10, 2026, 4:01 PM EDT

Filing Type: 8-K

Importance Score:

Vir Biotechnology Announces Departure of Chief Medical Officer

Price at Filing: $9.50

Real-time Price: $8.46

Change: -$1.04 (-11%)

Market Cap: $1.452B

Sentiment: Negative

View Wiseek Article

VIR

Mar 02, 2026, 9:03 AM EST

Source: Unknown

Importance Score:

Vir Biotechnology Finalizes $172.5M Equity Raise, Confirming 20.29M Share Dilution

Price at Filing: $8.86

Real-time Price: $8.46

Change: -$0.400 (-5%)

Market Cap: $1.452B

Sentiment: Negative

View Wiseek Article

VIR

Mar 02, 2026, 9:01 AM EST

Filing Type: 8-K

Importance Score:

Vir Biotechnology Closes $172.5 Million Public Offering, Underwriters Fully Exercise Option

Price at Filing: $8.79

Real-time Price: $8.46

Change: -$0.330 (-4%)

Market Cap: $1.452B

Sentiment: Neutral

View Wiseek Article

VIR

Feb 26, 2026, 5:23 PM EST

Source: Unknown

Importance Score:

Vir Biotechnology Prices $8.50 Equity Offering; About $141M Net Proceeds, Goldman Leads

Price at Filing: $9.25

Real-time Price: $8.46

Change: -$0.790 (-9%)

Market Cap: $1.452B

Sentiment: Negative

View Wiseek Article

VIR

Feb 26, 2026, 5:20 PM EST

Filing Type: 8-K

Importance Score:

Vir Biotechnology Prices $141.1M Public Offering at $8.50/Share

Price at Filing: $9.31

Real-time Price: $8.46

Change: -$0.850 (-9%)

Market Cap: $1.452B

Sentiment: Neutral

View Wiseek Article

VIR

Feb 24, 2026, 4:31 PM EST

Filing Type: 424B5

Importance Score:

Vir Biotechnology Announces $200 Million Common Stock Offering to Fund R&D and Astellas Collaboration

Price at Filing: $9.12

Real-time Price: $8.46

Change: -$0.660 (-7%)

Market Cap: $1.452B

Sentiment: Negative

View Wiseek Article

VIR

Feb 23, 2026, 5:27 PM EST

Filing Type: 10-K

Importance Score:

Vir Biotechnology Secures Major Oncology Partnership with Astellas, Bolstering Pipeline and Extending Cash Runway

Price at Filing: $11.88

Real-time Price: $8.46

Change: -$3.42 (-29%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

VIR

Feb 23, 2026, 5:16 PM EST

Filing Type: 8-K

Importance Score:

Vir Bio Secures $1.7B+ Astellas Oncology Partnership & Reports Strong Phase 1 Prostate Cancer Data

Price at Filing: $10.89

Real-time Price: $8.46

Change: -$2.43 (-22%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

VIR

Jan 14, 2026, 9:00 PM EST

Filing Type: 144

Importance Score:

Institutional Investor Files Intent to Sell $8.5M in Vir Biotechnology Stock

Price at Filing: $6.87

Real-time Price: $8.46

Change: +$1.59 (+23%)

Market Cap: $1.452B

Sentiment: Negative

View Wiseek Article

VIR

Jan 12, 2026, 8:07 AM EST

Filing Type: 8-K

Importance Score:

Vir Biotechnology Reports Strong Phase 2 CHD Data and Extends Cash Runway into Q4 2027

Price at Filing: $5.81

Real-time Price: $8.46

Change: +$2.65 (+46%)

Market Cap: $1.452B

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile